---
title: "IMMUNEONCO-B: Application for Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma"
description: "IMMUNEONCO-B has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China. IMM0306 is a bispecific molecule targeting CD47 and CD20"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/259374214.md"
published_at: "2025-09-29T15:01:03.000Z"
---

# IMMUNEONCO-B: Application for Phase III Clinical Trial of IMM0306 for the Treatment of Follicular Lymphoma

> IMMUNEONCO-B has submitted an application for the Phase III clinical trial of IMM0306 to the National Medical Products Administration of China. IMM0306 is a bispecific molecule targeting CD47 and CD20, the first of its kind to enter clinical stages globally. The drug enhances the activity of macrophages and NK cells by inhibiting the CD47-SIRPα interaction, effectively eliminating malignant B cells, reducing toxicity, and improving therapeutic efficacy. The company holds global intellectual property and commercialization rights for IMM0306

According to the Zhitong Finance APP, IMMUNEONCO-B (01541) announced that the group has submitted an application for the Phase III clinical trial of IMM0306 to the Center for Drug Evaluation of the National Medical Products Administration of China.

IMM0306, independently developed by the group, is a bispecific molecule targeting Cluster of Differentiation 47 (CD47) and Cluster of Differentiation 20 (CD20), and is the world's first CD47 and CD20 dual-target bispecific molecule to enter the clinical stage. IMM0306 blocks the "don't eat me" signal by inhibiting the CD47-SIRPα interaction, enhances the Fc-FcɣRIIa and Fc-FcɣRIIIa interactions to activate macrophages and NK cells, and preferentially binds to CD20 rather than CD47 to effectively eliminate malignant B cells while minimizing toxicity, thereby improving therapeutic efficacy.

As of the date of this announcement, the group holds global intellectual property and commercialization rights for IMM0306

### Related Stocks

- [01541.HK - IMMUNEONCO-B](https://longbridge.com/en/quote/01541.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Immuneonco Biopharmaceuticals Wins CDE Approval for Phase III Trial of IMM0306 in Follicular Lymphoma | Immuneonco Biopharmaceuticals has received approval from the Center for Drug Evaluation for a Phase III trial of IMM0306 | [Link](https://longbridge.com/en/news/267625269.md) |
| ImmuneOnco Completes Phase III Enrollment for Timdarpacept in CMML Treatment | ImmuneOnco Biopharmaceuticals has completed enrollment of 104 patients in a Phase III trial for IMM01 (Timdarpacept) tar | [Link](https://longbridge.com/en/news/273219066.md) |
| Elicera Therapeutics Reports Complete Remission in CARMA Lymphoma Study with ELC-301 Therapy | Elicera Therapeutics AB has reported that four out of six patients in its Phase I/IIa CARMA study achieved complete meta | [Link](https://longbridge.com/en/news/275613048.md) |
| CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CStone Pharmaceuticals has received FDA clearance for its IND application to initiate a Phase II clinical trial of its t | [Link](https://longbridge.com/en/news/276018493.md) |
| 17:28 ETINTA Annual Meeting Registration Surpasses 6,000, Attracting Stellar Speaker Roster | The International Trademark Association (INTA) announces that its 148th Annual Meeting, scheduled for May 2–6, 2026, in  | [Link](https://longbridge.com/en/news/275668932.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.